CAR-NK cell therapy (City of Hope)

N/A

Report date: 2025/01/26 19:11:43

Base Information

Drug NameCAR-NK cell therapy (City of Hope)

Drug Alias Nameanti-SARS-CoV-2 spike protein CAR NK-cell therapy (City of Hope)mACE2-CAR_sIL15 NK cell therapy (City of Hope)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionAngiotensin-converting enzyme 2 modulatorsInterleukin-15 receptors agonistsCoronavirus spike glycoprotein modulators

TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoproteinInterleukin-15 receptors

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCity of Hope

China Registration ClassN/A

Develop Information

Active CompaniesCity of Hope

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A